<DOC>
	<DOCNO>NCT01821482</DOCNO>
	<brief_summary>The purpose study evaluate efficacy Dendritic Cytokine-induced Killer Cells ( DC-CIK ) hepatocellular carcinoma ( HCC ) .</brief_summary>
	<brief_title>A Study DC-CIK Treat Hepatocellular Carcinoma</brief_title>
	<detailed_description>About 60 patient HCC , receive complete resection TACE get Complete remission ( CR ) partial response ( PR ) , randomly divide group A ( receive DC-CIK treatment ) group B ( regularly follow ) , randomize ratio 1:1 . Patients group A receive 2-3 cycle DC-CIK cell treatment ( every 4 week ) . Patients group B anti-tumor therapy .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>1 . Male female patient &gt; 18 year age ; 2 . Hepatocellular carcinoma histological imaging AFP diagnose , receive complete resection TACE get CR PR image study ; 3 . Patients life expectancy least 12 week ; 4 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 ; 5 . The bone marrow function normally ( WBC &gt; 4.0×109/L , Hb &gt; 120 g/L , PLT &gt; 100×109/L ) ; 6 . The ECG result normal , liver kidney functional . 1 . Patients distant metastasis ; 2 . Patients uncontrolled infection ; underlying disease severe lifethreatening ; 3 . Patients pregnant lactating ; 4 . ECOG perform status ≥ 2 ; 5 . Patients suffer auto immune diseases patient need accept glucocorticoid treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Hepatocellular carcinoma , DC-CIK</keyword>
</DOC>